Search

Displaying results 4981 - 4990 of 8010 in total
  1. Target

    Immunoglobulin heavy variable 3-30

    go.drugbank.com/bio_entities/BE0004312
    TargetHumans

    Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. … variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for

    Synonyms: Ig heavy chain V-III region BUR
  2. Drug

    Orbifloxacin

    go.drugbank.com/drugs/DB11443
    ExperimentalVet approved

    It is marketed by Schering-Plough Animal Health and approved for certain infections in dogs.

  3. Drug

    Articaine

    go.drugbank.com/drugs/DB09009
    ApprovedInvestigational

    Articaine is a dental local anesthetic. Articaine is widely used around the world and is the most popular local anesthetic in many European countries.

    Mixtures: FULLCAIN FORT AMPUL , 100 AMPUL, FULLCAIN FORT AMPUL , 20 AMPUL
  4. Drug

    ALS-08

    go.drugbank.com/drugs/DB05705
    Experimental

    ALS-08 is a proprietary creatine-derivative that is being developed as a potential therapeutic for amyotrophic lateral sclerosis (ALS). It is being developed by Avicena Group, Inc.

  5. Drug

    Alipogene tiparvovec

    go.drugbank.com/drugs/DB13521
    Approved

    It is being investigated for the treatment of lipoprotein lipase (LPL) deficiency.[A259796, A259801, A259806, A259811]

  6. Drug

    PPI-1019

    go.drugbank.com/drugs/DB05832
    Investigational

    Apan (PPI-1019) is developed by Praecis Pharmaceuticals to treat Alzheimer's Disease.

  7. Drug

    Methyl (2S)-2-[[2-[(3R)-1-carbamimidoylpiperidin-3-yl]acetyl]amino]-3-[4-(2-phenylethynyl)phenyl]propanoate

    go.drugbank.com/drugs/DB03453
    Experimental

    Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids.

  8. Drug

    RTA 744

    go.drugbank.com/drugs/DB05920
    Investigational

    RTA 744 is a novel anthracycline derivative that crosses the blood-brain barrier and shows significant potential for the treatment of primary and metastatic brain cancers.

  9. Drug

    Tetrathiomolybdate

    go.drugbank.com/drugs/DB05088
    Investigational

    COPREXA has completed pivotal clinical trials for the treatment of neurologic Wilson's disease. … Tetrathiomolybdate is an oral, small-molecule, anticopper agent that is highly specific for lowering the levels of free copper in serum.

    Categories: Compounds used in a research, industrial, or household setting
  10. Drug

    ATX-201

    go.drugbank.com/drugs/DB05765
    Investigational

    It is developed by Kythera Biopharmaceuticals, Inc. for the treatment of actinic keratosis. The company announced the decision to discontinue its ATX-201 clinical program for actinic keratosis.